- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.08. | BIO-WORKS TECHNOLOGIES AB: Bio-Works brings forward the publication of its interim report for the third quarter of 2026 | 1 | Cision News | ||
| 25.08. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Secures New US Customer in the Development of Next-Generation Medicine | 2 | Cision News | ||
| BIO-WORKS TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 21.08. | BIO-WORKS TECHNOLOGIES AB: Bio-Works reports second quarter 2026 | 1 | Cision News | ||
| 18.08. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB appoints Eva Lindskog as new CEO | 1 | Cision News | ||
| 17.07. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Receives Order for 22,6 MSEK from Returning Customer | 2 | Cision News | ||
| 15.07. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB announces outcome from exercise of warrants of series TO 2. Exercise period 7 of 11 | 1 | Cision News | ||
| 06.07. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Receives Order for 8,9 MSEK from Returning Customer | 1 | Cision News | ||
| 01.07. | BIO-WORKS TECHNOLOGIES AB: Today is the first day of the seventh exercise period for Bio-Works Technologies AB's warrants of series TO 2 | 1 | Cision News | ||
| 01.07. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB - Business Update second quarter 2026 | 1 | Cision News | ||
| 04.06. | BIO-WORKS TECHNOLOGIES AB: Resolutions passed at Bio-Works Technologies' annual general meeting 2026 | 1 | Cision News | ||
| 13.05. | BIO-WORKS TECHNOLOGIES AB: Bio-Works reports first quarter 2026 | 2 | Cision News | ||
| 29.04. | BIO-WORKS TECHNOLOGIES AB: Bio-Works receives order for WorkBeads 40S from contract manufacturer in Europe | 1 | Cision News | ||
| 17.04. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB announces outcome from exercise of warrants of series TO 2. Exercise period 6 of 11 | 8 | Cision News | ||
| 10.04. | BIO-WORKS TECHNOLOGIES AB: Proposed New Board Members in Bio-Works | 1 | Cision News | ||
| 01.04. | BIO-WORKS TECHNOLOGIES AB: Today is the first day of the sixth exercise period for Bio-Works Technologies AB's warrants of series TO 2 | 3 | Cision News | ||
| 01.04. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB - Business Update first quarter 2026 | 13 | Cision News |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HELIX BIOPHARMA | 0,715 | -19,21 % | Helix BioPharma Corp (2): Helix BioPharma appoints Loeffler as CMO | ||
| DAMORA THERAPEUTICS | 26,580 | 0,00 % | Damora Therapeutics, Inc.: Damora Announces Redomestication from Delaware to Cayman Islands | BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (Damora or the Company) (NASDAQ: DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders... ► Artikel lesen | |
| ERASCA | 16,050 | 0,00 % | FDA Fast Track Puts Erasca's (ERAS) Pancreatic Bet Center Stage | ||
| QIAGEN | 36,615 | -0,01 % | QIAGEN N.V. - 6-K, Report of foreign issuer | ||
| TANGO THERAPEUTICS | 23,360 | -2,75 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| DYNE THERAPEUTICS | 18,050 | -5,94 % | Aktien New York Ausblick: Dow schwächelt weiter - Nasdaq stabil erwartet | NEW YORK (dpa-AFX) - Die US-Börsen steuern nach dem verlängerten Wochenende am Dienstag auf eine durchwachsene Eröffnung zu. Auf die Stimmung drückten die weiter steigenden Ölpreise, die der Angst... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,950 | -3,36 % | Mercks 30-Milliarden-Dollar-Blockbuster bekommt neue Konkurrenz - warum Big Pharma schon die nächste Plattform sucht | ||
| KYMERA THERAPEUTICS | 118,49 | +2,65 % | Kymera Therapeutics auf Citigroup-Gipfel: Offensive bei oralen Immunologie-Medikamenten gewinnt an Fahrt | ||
| BEAM THERAPEUTICS | 24,200 | -3,87 % | Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 | BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months... ► Artikel lesen | |
| RELAY THERAPEUTICS | 19,050 | +2,04 % | Relay Therapeutics: Zovegalisib-Pipeline steht vor entscheidenden Meilensteinen | ||
| COGENT BIOSCIENCES | 33,660 | -1,43 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| VERA THERAPEUTICS | 33,540 | -0,71 % | Vera Therapeutics: Erfolgreicher Start für Nierenmedikament TRUTAKNA | ||
| TYRA BIOSCIENCES | 23,550 | +7,00 % | Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib | TYRA's mission is to make dabogratinib the clear first-line treatment choice for patients with LG IR NMIBC
Favorable safety and tolerability results support chronic... ► Artikel lesen | |
| ALUMIS | 9,910 | +1,12 % | Alumis-Aktie: No Brainer Club feiert zweistellige Kursgewinne zum Start | Gewohnt gutes Timing: Der No Brainer Club hat auch bei Alumis im richtigen Moment zugeschlagen und blickt bereits nach einem Tag auf zweistellige Kursgewinne. Nach dem massiven Abverkauf infolge enttäuschender... ► Artikel lesen | |
| IMMUNOVANT | 37,790 | -2,48 % | Immunovant, Inc. - 8-K, Current Report |
BIO-WORKS TECHNOLOGIES AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,264 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIO-WORKS TECHNOLOGIES AB finden Sie auf Wallstreet Online.